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SUMMARY 
Background: Asthma diagnosis is based on the presence of symptoms and the demonstration of airflow 
variability. Airway inflammation measured by fractional exhaled nitric oxide, measured at a flow rate of 50 ml/s 
(FENO50) remains a controversial diagnostic tool. Aim: To assess the ability of FENO50 to identify bronchial 
hyperresponsiveness (BHR) to methacholine (provocative concentration of methacholine causing a 20% fall in 
FEV1; PC20M ≤ 16 mg/ml) and to establish whether or not symptoms relate to FENO50 and PC20M in patients 
with no demonstrated reversibility to β2-agonist. Methods: We conducted a prospective study on 174 steroid 
naive patients with respiratory symptoms, forced expiratory volume in 1 s (FEV1) ≥ 70% predicted and no 
demonstrated reversibility to β2-agonist. Patients answered to a standardised symptom questionnaire and 
underwent FENO50 and methacholine challenge. Receiver-operating characteristic (ROC) curve and logistic 
regression analysis assessed the relationship between PC20M and FENO50. taking into account covariates 
(smoking, atopy, age, gender and FEV1). Results: A total of 82 patients had a PC20M ≤ 16 mg/ml and had 
significantly higher FENO50 (19 ppb vs. 15 ppb; p < 0.05). By constructing ROC curve, we found that FENO50 cut-
off value of 34 ppb was able to identify not only BHR with high specificity (95%) and positive predictive value 
(88%) but low sensitivity (35%) and negative predictive value (62%). When combining all variables into the 
logistic model, FENO50 (p = 0.0011) and FEV1 (p < 0.0001) were independent predictors of BHR whereas age, 
gender, smoking and atopy had no influence. The presence of diurnal and nocturnal wheezing was associated 
with raised FENO50 (p < 0.001 and p < 0.05, respectively). Conclusion: The value of FENO50 > 34 ppb has high 
predictive value of PC20M < 16 in patients with suspected asthma in whom bronchodilating test failed to 
demonstrate reversibility or was not indicated. However, FENO50 ≤ 34 ppb does not rule out BHR and should 
prompt the clinician to ask for a methacholine challenge. 
What's known 
Fractional exhaled nitric oxide (FENO) is a noninvasive marker of eosinophilic airway inflammation. Some 
studies have suggested it may be helpful in diagnosing asthma but it remains debated. 
What's new 
We conducted a field study assessing the potential of fractional exhaled nitric oxide, measured at a flow rate of 
50 ml/s (FENO50) in steroid-naive patients with suspected asthma sent by respiratory physicians to a routine 
function laboratory to perform a methacholine challenge. Our results show that FENO50 > 34 ppb had a high 
positive predictive value to identify patients with significant bronchial hyperresponsiveness. However, FENO50 ≤ 
34 ppb does not rule out BHR and should prompt the clinician to ask for a methacholine challenge. We 
calculated that FENO measurement could spare methacholine challenge in 20% of patients. 
 
Introduction 
Asthma diagnosis is usually based on symptoms such as cough, breathlessness, dyspnoea and wheezing together 
with the demonstration of airflow variability. The airway inflammatory component of the disease is an important 
feature which is an integral part of the asthma definition (1). Airway inflammation can be non-invasively 
assessed by measuring sputum eosinophil count (2) and fractional exhaled nitric oxide, measured at a flow rate 
of 50 ml/s (FENO50) (3), the latter being much more convenient to apply in routine as it yields immediate results. 
Both sputum eosinophil count and FENO50 have been proposed as a useful diagnostic tool in mild to moderate 
asthma. In this group of patients airway inflammatory markers proved to be superior to classic FEV1 reversibility 
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to β2-agonist or to peak expiratory flow (PEF) variability criteria (4,5). FENO50 was shown to reflect airway 
eosinophilic inflammation in asthma patients seen in clinical practice (6,7). 
Asthma diagnosis remains a challenge in clinical practice (8) and either reversibility test or bronchial 
provocation challenge is required to confirm the diagnosis. There is a need for a simple, quick and reliable test in 
those patients with suggestive symptoms of asthma. Early studies have suggested that fractional exhaled nitric 
oxide, measured at a flow rate of 200 ml/s (FENO200) cut-off of 16 ppb may help to identify patients with 
bronchial hyperresponsiveness to histamine or reversibility to β2-agonist among those presenting with chronic 
respiratory symptoms and normal baseline lung function (9). Factor analysis has, however, revealed that airway 
inflammation and bronchial hyperresponsiveness towards methacholine load in different clusters in patients with 
long disease duration (10,11). On the other hand, FENO20 has been shown to correlate with new onset wheeze in 
longitudinal population study (12). 
Airway hyperresponsiveness assessed by methacholine challenge is time consuming and unpleasant to the 
patient whereas fractional exhaled nitric oxide (FENO) measurement is easy to perform and provides immediate 
results. The purpose of our study was to see how FENO measured at a flow rate of 50 ml/s may actually reflect 
the presence of methacholine bronchial hyperresponsiveness assessed by the provocative concentration that 
causes a 20% fall in FEV1 (PC20M) in patients referred by chest physicians for asthma diagnosis to a routine 
laboratory function. This study focused on patients in whom the bronchodilation test did not allow to ascertain 
asthma diagnosis either because of being negative or not done given a high baseline forced expiratory volume in 
1 s (FEV1) value (> 80% predicted and FEV1/FVC > 70%). We also sought to establish how different types of 
respiratory symptoms relate to FENO50 and PC20M. 
Methods 
Subject characteristics and study design 
We conducted a prospective study on a series of 237 patients recruited from the University Hospital of Liege 
between March 13, 2009 and December 30, 2009. These patients were addressed by their respiratory physician 
for a methacholine challenge to detect asthma. Subjects referred to methacholine challenge were those in whom 
the bronchodilating test failed to demonstrate reversible airways obstruction or those in whom baseline 
spirometric values were normal giving a low probability for a bronchodilating test to be significant. The patients 
studied here had either baseline FEV1 ≥ 80% predicted and FEV1/FVC ratio ≥ 70% or bronchodilation < 12% 
from baseline and 200 ml after 400 µg inhaled salbutamol in case of baseline FEV1 was < 80% predicted or 
FEV1/FVC ratio < 70%. Patients already receiving inhaled corticosteroids were excluded from the study. The 
demographic and functional characteristics of the 174 corticosteroid naïve patients are summarised in Table 1. 
 
Table 1    Demographic, functional and inflammatory characteristics for 174 steroid naive patients 
No. 174 
Sexe (M/F) 72/102 
Age, years 41 ± 16 
Atopy (Y/N) 84/90 
Current smoking (Y/N) 59/115 (34%) 
PC20 < 16 mg/ml (Y/N) 82/92 
FEV1, % predicted 97 ± 13 
FVC, % predicted 100 ± 14 
FEV1/VC, % 83 ± 7 
FENO50, ppb 17 (4-271) 
Data are presented as mean ± SD (FEV1, FVC, FEV1/VC, age) or as median (range; FENO50). PC20M is expressed as geometric mean (range). 
PC20M, provocative concentration of methacholine causing a 20% fall in FEV1; FEV1, forced expiratory volume in one second; FVC, forced 
vital capacity; FENO50, fractional exhaled nitric oxide. 
 
After receiving and signing inform consent, patients were asked to complete a questionnaire concerning their 
symptoms and FENO was measured at a flow rate of 50 ml/s. The subjects underwent methacholine challenge 
after refraining from using bronchodilators for the appropriate time (8 h for short-acting bronchodilators and 24 h 
for long-acting bronchodilators) as long as the baseline FEV1 value was not less than 70% predicted. Asthma 
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was diagnosed based on airway hyperresponsiveness demonstrated by inhaled concentration of methacholine 
provoking a 20% fall in FEV1 of less than 16 mg/ml (13,14). Methacholine challenges were performed according 
to a slightly adapted Cockroff's tidal-breathing method as previously described (15). Subjects were characterised 
as atopic if they had at least one positive skin prick test (wheal > 3 mm as compared with negative control) or 
specific IgE (> 0.35 KU/l; Phadia) for at least one common aero-allergen (cat, dog, house dust mites, grass 
pollen, tree pollen and a mixture of moulds). This study was conducted with the approval of the Ethics 
Committee of CHU Liege. 
Questionnaires 
Symptoms were assessed using a standardised questionnaire which covered symptoms and smoking habits. 
Symptoms listed were diurnal and nocturnal cough, diurnal and nocturnal wheezing, dyspnoea, chest tightness, 
chest pain, exercise trigger, humidity trigger, fumes trigger, dust trigger, pollen trigger, emotional trigger, 
rhinitis, urticaria and pyrosis. 
Exhaled NO measurement 
Exhaled nitric oxide, FENO was measured by chemi-luminescence using a nitric oxide monitor set at a flow rate 
of 50 ml/s (NIOX, Aerocrine, Sweden). The analyser was calibrated daily with a known NO concentration. 
Statistical analyses 
Results were expressed as mean ± standard deviations (SD) for continuous variables. The median and range were 
preferred for skewed distributions. For categorical variables, the number of observations and percentages were 
given in each category. Comparisons between different subgroups were performed by using a Kruskal-Wallis 
test. The Receiver-operating characteristic (ROC) curve was constructed to determine the value of FENO50 which 
best identified a bronchial hyperresponsiveness in the whole population. Logistic regression analysis was used to 
assess the relationship between the binary outcome (PC20M ≤ 16 mg/ml) and a set of covariates, individually or 
in combination. Covariates included FENO50 (log transformed), age, gender, FEV1, smoking and atopy. The 
results were considered to be significant at the 5% critical level (p < 0.05). Calculations were done using SAS 
Version 9.1 (SAS Institute, Cary, North Carolina, USA). 
Table 2 Demographic, functional and inflammatory characteristics for patients with and without asthma 
 PC20M ≤ 16 mg/ml PC20M > 16 mg/ml 
N. 82 92 
Sexe (M/F) 33/49 39/53 
Age, years 38 ± 18* 44±15 
Atopy (Y/N) 43/39 (52%) 41/51 (45%) 
Smoking (Y/N, %) 25/57 (30%) 34/58 (37%) 
PC20, mg/ml 2.44 (0.02-16)  
DRS FEV1 (%/µmol) 0.0033 (0.0006-0.4337)*** 0.0004 (0.0001-0.0007) 
FEV1, % predicted 95 ± 14** 102 ± 12 
FVC, % predicted 99 ± 14 102 ± 13 
FEV1/VC, % 82 ± 7* 84 ± 6 
FENO50, (PPb) 19 (4-271)* 15 (4-120) 
Data are presented as mean ± SD (FEV1, FVC, FEV1/VC, age) or as median (range; FENO50)· PC20M is expressed as geometric mean (range), 
*p < 0.05, **p < 0.001, ***p < 0.0001. PC20M, provocative concentration of methacholine causing a 20% fall in FEV1; DRS, dose-response 




Among the 174 patients referred for a methacholine challenge, 82 had a PC20M ≤ 16 mg/ml and were thus 
considered as being asthmatics. The demographic and functional characteristics of patients according to their 
level of bronchial responsiveness towards methacholine are given in Table 2. Patients with positive methacholine 
challenge had lower baseline FEV1 (95% predicted vs. 102% predicted, p < 0.001) and lower FEV1/FVC (p < 
0.05) even if the average value clearly remained within the normal range. FENO50 was significantly higher in 
Published in : International Journal of Clinical Practice (2012), vol. 66, iss. 2, pp. 158-165. 
Status : Postprint (Author’s version) 
 
patients with positive methacholine challenge than in their negative counterparts (19 ppb vs. 15 ppb, p < 0.05). 
When combining all variables into the logistic model, FENO50 (p = 0.0011) and FEV1 (p < 0.0001) were 
independent predictors of bronchial hyperresponsiveness to methacholine whereas age (p = 0.12), gender (p = 
0.56), smoking status (p = 0.56) and atopy (p = 0.65) were not significant (Table 3). Lower baseline FEV1  
values and higher FENO values were associated with PC20M ≤ 16 mg/ml. 
We constructed a ROC curve to establish the ability of FENO50 to identify bronchial hyperresponsiveness 
assessed by methacholine challenge (Figure 1). We found that FENO50 significantly predicted PC20 ≤ 16 mg/ml 
with a cut-off value of 34 ppb. However, this FENO50 cut point offers much greater specificity (95%) and positive 
predictive value (PPV) (88%) than sensitivity (35%) and negative predictive value (NPV) (62%). In patients 
with a negative methacholine challenge the upper limit of the 95% CI of FENO50 was 35 ppb. When referring to 
FENO50 normal values as defined by Travers et al. (16), we found that 22 patients (13%) had FENO50 values upper 
to the 95% confidence interval. The ability of FENO50 to identify airway hyperresponsiveness was high in those 
patients. Indeed 20 of the 22 patients with FENO50 values out of range according to Travers had bronchial 
hyperresponsiveness whereas this was only the case in 62 of the 152 patients in whom FENO50 was within the 
normal range according to Travers et al. (Odds ratio 14.5, p < 0.0001). 
We constructed a ROC curve to identify which FEV1 cut-off was best related to the prediction of the presence of 
a bronchial hyperresponsiveness (Figure 2). We found that FEV1 significantly predicted PC20M ≤ 16 mg/ml 
with a cut-off value of 101%. The sensitivity and specificity of this threshold was 71% and 57%, respectively (p 
= 0.0001, AUC = 0.67). 
When combining FENO50 and FEV1 values to predict the presence of a bronchial hyperresponsiveness to 
methacholine, we found that the presence of both FENO50 > 34 ppb and FEV1 ≤ 101% predicted gave a high 
specificity (98.9%) but a poor sensitivity (24.4%) for identifying patients with positive methacholine challenge 
(Table 4). 
Relationship between FENO and methacholine responsiveness 
On the whole population the dose-response slope (DRS) for methacholine weakly correlated with FENO50 (r = 
0.18; p = 0.03). Among those patients positive to methacholine there was, however, no relationship between the 
magnitude of bronchial hyperresponsiveness (PC20M) and the level of FENO50 (r = -0.06, p = 0.6, Figure 3). 
Relationship between respiratory symptoms and FENO50 or bronchial responsiveness 
Table 5 shows FENO50 according to the presence of respiratory symptoms in our population. Diurnal and 
nocturnal wheezing were associated with raised levels of FENO50 (p < 0.001 and p < 0.05, respectively). Table 6 
shows the proportion of symptoms according to the results of methacholine challenge. Patients reporting 
dyspnoea, diurnal and nocturnal wheezing and chest tightness were more likely to have positive methacholine 
challenge. 
 
Table 3 Relationship between bronchial hyperresponsiveness to methacholine and a set of covariates including 




Parameter Coefficient ± SE p-value 
Intercept 3.82 ± 1.47 0.0091 
LnFENO 0.82 ± 0.25 0.0011 
Smoking -0.22 ± 0.37 0.56 
Age -0.02 ± 0.01 0.12 
FEV1 -0.06 ± 0.01 < 0.0001 
LnFENO*atopy 0.05 ± 0.11 0.65 
Sex -0.19 ± 0.33 0.56 
FENO50, fractional exhaled nitric oxide; FEV1, forced expiratory volume in one second. Multiple logistic regression analysis. The binary 
outcome was bronchial hyperresposiveness to methacholine (PC20M ≤ ou > 16 mg/ml). Covariates included FENO (log-transform), smoking 
status, age, FEV1, atopy and gender. When combining all variables into the logistic model, we found that only FENO and FEV1 were 
significant predictors of the presence of a bronchial hyperresponsiveness to methacholine. Akaike's Criterion (AIC) reached a minimum for 
this model (AIC = 206.2). 
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Table 4 Combination of FENO50 and FEV1 to predict the presence of a bronchial hyperresponsiveness to 
methacholine challenge according to FENO50 and FEV1 cut-off value defined by the ROC curve 
  PC20M ≤ 16 (n = 82) PC20M > 16 (n = 92) Frequence 
ratio A/B FENO50 FEV1 n % (A) n % (B) 
> 34 ≤ 101 20 24.4 1 1.1 22.4 
> 34 > 101 11 13.4 2 2.2 6.2 
≤ 34 ≤ 101 39 47.6 40 43.5 1.1 
≤ 34 > 101 12 14.6 49 53.3 0.3 
FENO50, fractional exhaled nitric oxide; FEV1, forced expiratory volume in one second; PC20M, provocative concentration of methacholine 
causing a 20% fall in FEV1. When FENO50 value > 34 ppb is associated with FEV1 ≤ 101% predicted, 24.4% of patients have bronchial 
hyperresponsiveness to methacholine and are thus true positives while there are only 1.1% of false positive. When FENO50 value is ≤ 34 ppb 
and FEV1 > 101%, 53.3% of the patients didn't have bronchial hyperresponsiveness to methacholine and were thus true negatives while 
14.6% were false negative, fhe combination of FENO50 and FEV1 gave a high specificity (98.9%) but a poor sensitivity (24.4%) for 
identifying patients with a positive bronchial hyperresponsiveness to methacholine. fhe table also shows that the presence of a FENO50 > 34 
ppb is more frequently associated to FEV1 ≤ 101 % in patients with bronchial hyperresponsiveness than in patients without asthma (ratio = 
22.4). This ratio decreases if either FENO50 or FEV1 cut-off is not reached. A FENO50 value ≤ 34 ppb associated with FEV1 > 101% is however 
more frequently encountered in patients with negative methacholine challenge (ratio = 1/0.3 = 3.3). 
 
Figure 1  Receiver-operating characteristic curve (ROC) for the whole group determining exhaled nitric oxide 
value which best identified the provocative concentration of methacholine causing a 20% fall in forced 
expiratory volume in 1 s, FEV1 ≤ 16 mg/ml. Cut-off point: 34 ppb (Specificity: 95.4%, Sensitivity: 35.4%, 
positive predictive value: 88%, negative predictive value: 62%, p = 0.0033. AUC = 0.62) 
 
 
Figure 2 Receiver-operating characteristic curve (ROC) for the whole group determining % predicted forced 
expiratory volume in 1 s (FEV1) value which best identified the provocative concentration of methacholine 
causing a 20% fall in FEV1 ≤ 16 mg/ml. Cut-off point: 101% (Specificity: 57%, Sensitivity: 71%, positive 
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Figure 3 Spearman test for patients exhibiting a 20% fall in forced expiratory volume in one second (FEV1) for 
a provocative concentration of methacholine ≤ 16 mg/ml We didn't find any correlation between fractional 
exhaled nitric oxide, measured at a flow rate of 50 ml/s (FENO50) and provocative concentration of methacholine 
causing a 20% fall in FEV1 (PC20M) in those patients considered as asthmatics (r = -0.06, p = 0.59) 
 
 
Table 5 FENO50 according to the presence of respiratory symptoms in a population of patients referred for 
asthma diagnosis 
 FENO50 (PPb) 




Diurnal cough 16 (4-271) 19 (4-213) 
 N = 122 N = 52 
Nocturnal cough 14 (4-213) 19 (4-271) 
 N = 62 N= 112 
Diurnal wheezing 20 (7-271)** 14 (4-213) 
 N = 82 N = 92 
Nocturnal wheezing 20 (5-213)* 15 (4-271) 
 N = 65 N = 119 
Dyspnoea 17 (5-213) 15 (4-271) 
 N = 111 N = 63 
Chest tightness 16 (5-271) 18 (4-142) 
 N = 115 N = 59 
Chest pain 14 (4-80) 18 (4-271) 
 N = 46 N = 128 
Exercice trigger 15 (5-213) 19 (4-271) 
 N = 99 N = 75 
Humidity trigger 15 (4-213) 18 (4-271) 
 N = 64 N = 110 
Fumes trigger 17 (4-150) 18 (4-271) 
 N = 87 N = 87 
Dust trigger 19 (5-142) 16 (4-271) 
 N = 78 N = 96 
Pollen trigger 19 (5-118) 16 (4-271) 
 N = 50 N = 124 
Emotional trigger 15 (5-213) 18 (4-271) 
 N =77 N = 97 
Rhinitis 17 (4-142) 17 (4-271) 
 N = 95 N = 79 
Urticaria 19 (5-213) 16 (4-271) 
 N = 48 N = 126 
Pyrosis 15 (4-142) 19 (5-271) 
 N = 91 N = 83 
*p < 0.05, **p < 0.001. FENO50, fractional exhaled nitric oxide. 
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Table 6 Proportion of symptoms according to the results of the methacholine challenge in a population referred 
for asthma diagnosis 
 PC20M < PC20M > 
Symptoms 16 mg/ml 16 mg/ml 
Diurnal cough (Y/N, %) 54/28 (66) 68/24 (74) 
Nocturnal cough (Y/N, %) 30/52 (37) 32/60 (35) 
Diurnal wheezing (Y/N, %) 47/35 (57)* 35/57 (38) 
Nocturnal wheezing (Y/N, %) 46/36 (56)** 19/73 (21) 
Dyspnoea (Y/N, %) 60/22 (73)** 41/51 (45) 
Chest tightness (Y/N, %) 60/22 (73)** 37/55 (40) 
Chest pain (Y/N, %) 20/62 (24) 26/66 (28) 
Exercice trigger (Y/N, %) 53/29 (65) 46/46 (50) 
Humidity trigger (Y/N, %) 33/49 (40) 31/61 (34) 
Fumes trigger (Y/N, %) 40/42 (49) 47/45 (51) 
Dust trigger (Y/N, %) 42/40 (51) 36/56 (39) 
Pollen trigger (Y/N, %) 28/54 (34) 22/70 (24) 
Emotional trigger (Y/N, %) 37/45 (45) 40/52 (43) 
Rhinitis (Y/N, %) 49/33 (60) 46/46 (50) 
Urticaria (Y/N, %) 25/57 (30) 23/69 (25) 
Pyrosis (Y/N, %) 39/43 (48) 52/40 (57) 
*p < 0.05, **p < 0.0001. PC20M, provocative concentration of methacholine causing a 20% fall in FEV1. 
 
Discussion 
Our results shows that FENO50 > 34 ppb has a high positive predictive value to identify bronchial 
hyperresponsiveness to methacholine in patients who had respiratory symptoms suggestive for asthma and in 
whom the respiratory physician had no argument for airway flow variability either because baseline calibre was 
considered to be normal or because bronchodila-tion to inhaled β2-agonist was weak. However, the sensitivity of 
34 ppb cut-off is poor and FENO50 values below this threshold clearly do not rule out bronchial    
hyperresponsiveness. Furthermore, we found that, among a list of respiratory symptoms, wheezing was the 
symptom that was the most convincingly associated with raised FENO50. 
Airway hyperresponsiveness and airway inflammation are acknowledged to be key but largely independent 
features of asthma (10,11). In routine many asthmatics are diagnosed based on the association between chronic 
respiratory symptoms and the demonstration of airway variability. Reversibility to inhaled β2-agonist and 
methacholine/histamine bronchial challenge are the most common ways used to confirm suspected asthma. In 
those patients with normal baseline lung function it was shown that bronchodilation test and peak expiratory 
flow rate variability perform rather weakly to ascertain the diagnosis (4,5). FENO50 has been advocated as a 
useful tool to make asthma diagnosis in steroid naive patients with respiratory symptoms (5,9). The population 
selected in our study is somewhat slightly different from those described in previous studies in that only patients 
in whom asthma diagnosis remains uncertain after reversibility testing and/or baseline spirometry were sent to 
our routine function laboratory for a methacholine challenge. Furthermore, it is of interest to note that the 
proportion of atopic patients was rather low (50%) and the proportion of active smokers rather high (35%) for a 
population of mild to moderate steroid naive asthmatics. Dupont (9) and Smith (5) excluded smokers and the 
series of Smith et al. (5) included 76% of atopic subjects whereas their proportion was not mentioned in the 
study of Dupont et al. The relatively weak proportion of atopy and the presence of smokers certainly explain 
why the average FENO50 value in our series is clearly lower than that reported in patients attending an asthma 
clinic (7,17). 
Our results show that bronchial NO may predict methacholine hyperresponsiveness reflected by PC20M ≤ 16 
mg/ml with FENO50 cut-off > 34 ppb yielding 95% specificity and 88% positive predictive value. Our data show 
that 20% with confirmed asthma had FENO50 value > 34 ppb. In contrast to the specificity, sensitivity of 34 ppb 
threshold is poor and a value below this threshold clearly does not exclude the presence of bronchial 
hyperresponsiveness. It is important to realise that FENO50 and PC20M values are largely independent   variables. 
Indeed the correlation between DRS (dose-response slope) for methacholine and FENO50 is weak for the whole 
population and we did not find any significant relationship between FENO50 and PC20M in those patients 
diagnosed as asthmatics. This contrasts with what we have recently found concerning the relationship between 
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FENO50 and sputum eosinophils in a large heterogeneous series of asthmatics encountered in daily practice (7). 
The relationship between FENO and airway hyperresponsiveness is controversial and conflicting results have 
been published (5,18-23). Compared with our patients, the studies showing a more convincing relationship 
between FENO and bronchial hyperresponsiveness included a significantly higher proportion of atopic patients. 
We found, however, by a multiple regression analysis that atopy, in contrast to FENO50, was not an independent 
predictor of bronchial hyperresponsiveness. On the other hand, Smith et al. (5) used hypertonic saline, an 
indirect stimulus, to measure bronchial responsiveness. It is recognised that airway inflammation is better related 
to indirect than to direct bronchial hyperresponsiveness (24). 
Although FENO50 and PC20M reflect different dimensions in asthma, it does not exclude functional relationship 
between the two variables. It is admitted that part of the bronchial hyperresponsiveness in asthma is linked to an 
airway eosinophilic inflammation that can be attenuated by corticosteroids (25). 
Furthermore, nitric oxide may itself contribute to bronchial hyperresponsiveness by increasing airway oedema as 
it is a potent vasodilator responsible for plasma exudation from bronchial vessels (26) and the transformation of 
NO in peroxynitrite was shown to induce airway hyperresponsiveness in guinea pigs (27). This may explain the 
good specificity of FENO to detect methacholine responsiveness even if it is not perfect as increased FENO50 may 
be observed in other pathological conditions such as eosinophilic bronchitis (28) where bronchial 
hyperresponsiveness is absent. It is also interesting to notice that FENO50 values outside the normal range as 
defined by Travers et al. (16), whilst being rather rare in our series (13%), carries a high odds ratio (14.5) in 
favour of bronchial hyperresponsiveness. This observation highlights the fact that consistent airway 
inflammation may be a determinant factor of bronchial hyperresponsiveness. 
The multiple logistic regression analysis confirmed the effect of baseline airway calibre as a strong independent 
predictor of the presence of bronchial hyperresponsiveness to methacholine. Some studies have shown a 
correlation between FEV1 and bronchial hyperresponsiveness (22,29,30). This suggests that airway geometric 
factors are involved in the mechanisms of bronchial hyperresponsiveness in asthma. Beyond geometry there is 
also solid argument to support the role of bronchial smooth muscle dysfunction in determining 
hyperresponsiveness to direct constricting agent (31). Although atopy was shown to correlate with bronchial 
hyperresponsiveness in epidemiological and clinical studies (32), our data suggest that its influence may be 
mediated by an increase in airway inflammation as atopic patients clearly exhibited higher FENO50 than non-
atopic (19 ppb vs. 15 ppb, p < 0.01). We therefore believe that it is not atopy per se that matters in determining 
bronchial hyperresponsiveness but rather the fact that atopy may favour airway inflammation in case sensitised 
patients are exposed to a relevant allergen. It is important to emphasise that smoking status did not impact on 
bronchial hyperresponsiveness to methacholine in our study. Smoking has been shown to induce airway 
hyperresponsiveness in the general population (33). Our data show that smoking may be less critical when 
considering selected patients based on the presence of chronic respiratory symptoms. 
There are only limited data on the precise relationship between the type of symptoms and airway inflammation. 
In our study diurnal and nocturnal wheezing were associated with proximal airway inflammation as reflected by 
raised levels of FENO50. Leuppi et al. reported the same observation in a population of children (34). Although it 
is admitted that asthma may sometimes be revealed by isolated cough (35), our data show that cough is generally 
poorly related to methacholine hyperresponsiveness and to FENO50. As compared with FENO bronchial 
hyperresponsiveness to methacholine is associated with a broader spectrum of symptoms including not only 
wheezing but also dyspnoea and chest tightness which are likely to better reflect airflow limitation than 
wheezing alone. 
Our study had not the purpose to study asthma phenotypes but rather to validate an inflammometer as a 
diagnostic tool for the currently accepted definition of asthma according to GINA. A key issue is to know 
whether or not those patients with chronic respiratory symptoms and high FENO50 are better responsive to inhaled 
corticoids irrespective of their level of bronchial hyperresponsiveness and their 'asthma' label. This has been 
suggested by pilot monocentric study (36) but has to be confirmed in a study conducted on a larger scale. 
Conclusion 
We conclude that FENO measurement may be useful to the clinician in diagnosing asthma in patients with 
chronic respiratory symptoms in whom bronchodilating test failed to demonstrate reversibility or was not 
indicated. However, the poor sensitivity of FENO50 to detect bronchial hyperresponsiveness should prompt the 
clinician to ask for a methacholine challenge when asthma is suspected based on clinical history in case of 
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FENO50 < 34 ppb (Figure 4). According to our data, application of the algorithm proposed in Figure 3 could save 
20% of methacholine challenges performed in a routine pulmonary function laboratory. This is not to be 
neglected as methacholine challenge is time consuming and uncomfortable to the patients. 
 
Figure 4 Proposed algorithm for asthma diagnosis. Values < 34 ppb should prompt the clinician to ask for a 
methacholine challenge when asthma is suspected based on clinical history. The application of the proposed 
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